FLUOROQUINOLONE DERIVATIVES OR SULFONAMIDE MOIETY-CONTAINING COMPOUNDS AS INHIBITORS OF TYROSYL-DNAPHOSPHODIESTERASE (TDP1)
First Claim
1. A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of a topoisomerase I (TopI) inhibitor and a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject. In certain embodiments, the fluoroquinolone derivative or sulfonamide moiety-containing compound is co-administered with a topoisomerase I (TopI) inhibitor.
-
Citations
22 Claims
- 1. A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of a topoisomerase I (TopI) inhibitor and a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject.
- 2. A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject.
-
3. A method for inhibiting tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity in a biological sample with Tdp1 activity, comprising contacting the biological sample with (i) a fluoroquinolone derivative that inhibits Tdp1 activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby inhibiting Tdp1 activity.
-
22. A pharmaceutical composition, comprising a therapeutically effective amount of a TopI inhibitor and a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits Tdp1 activity, or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity.
Specification